Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
167 pending office actions • 89 clients • 155 examiners • 88 art units • 0 of 167 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
MEDLER FERRO WOODHOUSE & MILLS PLLC handles Biotechnology & Pharmaceuticals matters across 2,599 career applications. The profile shows 171 pending office actions and a 77.91% resolved allowance rate.
The average is 3.55 office actions per allowance. The pending docket represents substantial ongoing activity, and the response average indicates that practitioners should anticipate continued prosecution work before allowance in resolved matters.
Based on the USPTO statutory response window for each pending office action. 63 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 63 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 4 (2%) |
| §101 + other | 17 (10%) |
| §103 only | 41 (25%) |
| §102 only | 2 (1%) |
| §112 only | 17 (10%) |
| Double-patenting only | 3 (2%) |
| Double-patenting + other | 19 (11%) |
| Multi-statute (no §101) | 64 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NATARAJAN, MEERA | 3 | 62.6% | +17.9% |
| TRAN, CHRISTINA L | 3 | 51.6% | +49.8% |
| PETRASH, HILARY ANN | 2 | 65.6% | +50.2% |
| CROW, ROBERT THOMAS | 2 | 41.6% | +32.5% |
| NERANGIS, VICKEY M | 2 | 56.6% | +28.9% |
| MOSELEY II, NELSON B | 2 | 67.9% | +41.7% |
| BRISTOL, LYNN ANNE | 2 | 63.4% | +39.8% |
| HILL, MYRON G | 2 | 66.1% | +20.7% |
| LY, KRISTINA ELISABETH | 2 | 37.5% | +100.0% |
| ROGERS, ERIC JASON | 2 | 56.9% | +33.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17562316 | METHOD FOR CONTROLLING AN EYE SURGICAL LASER, COMPUTER PROGRAM PRODUCT, AND TREATMENT APPARATUS | CHRISTIANSON, SKYLAR LINDSEY | 282d overdue |
| 18258502 | MODIFIED PARAPOXVIRUS HAVING INCREASED IMMUNOGENICITY | VIJAYARAGHAVAN, JAGAMYA NMN | 98d overdue |
| 17290061 | Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies | SITTON, JEHANNE SOUAYA | 88d overdue |
| 18258501 | MODIFIED PARAPOXVIRUS HAVING INCREASED IMMUNOGENICITY | HILL, MYRON G | 79d overdue |
| 18005438 | EXQUISITE VEGAN CONVENIENCE FOODS AND PRODUCTION THEREOF | MERCHLINSKY, JOSEPH CULLEN | 56d overdue |
| 18631297 | METHOD FOR PROVIDING CONTROL DATA FOR AN OPHTHALMOLOGICAL LASER OF A TREATMENT APPARATUS FOR AVOIDING AN OPAQUE BUBBLE LAYER | LEVICKY, WILLIAM J | 45d overdue |
| 18005917 | STIMULATION ARRANGEMENTS, VENTILATION ARRANGEMENT, STIMULATION METHODS AND VENTILATION METHOD | REDDY, SUNITA | 43d overdue |
| 17344792 | METHOD FOR ISOLATING POLY(A) NUCLEIC ACIDS | HANEY, AMANDA MARIE | 42d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258501 | MODIFIED PARAPOXVIRUS HAVING INCREASED IMMUNOGENICITY | HILL, MYRON G | 79d overdue |
| 18320599 | TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | BRISTOL, LYNN ANNE | 23d overdue |
| 18554935 | MODIFIED VIRUS-LIKE PARTICLES OF BACTERIOPHAGE AP205 | HILL, MYRON G | 4d overdue |
| 17635322 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | TRAN, CHRISTINA L | 7d |
| 17999288 | SERUM-FREE INDUCTION METHOD FOR SENSORY NEURON CELL | ROGERS, ERIC JASON | 14d |
| 18675357 | CELLULOSIC COMPOSITE | NERANGIS, VICKEY M | 33d |
| 18253160 | ADJUVANT CONTAINING ZINC ALUMINUM RISEDRONATE, AND APPLICATION THEREOF | LY, KRISTINA ELISABETH | 40d |
| 18969940 | ANTI-PSMA ANTIBODY CONJUGATES | PETRASH, HILARY ANN | 41d |
| Art Unit | Apps |
|---|---|
| 3796 | 8 |
| 1637 | 8 |
| 1643 | 7 |
| 1671 | 5 |
| 1654 | 5 |
| 1644 | 4 |
| 1683 | 4 |
| 3783 | 4 |
| 3791 | 4 |
| 1642 | 4 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19544916 | FLUORESCENCE IMAGING SYSTEM FOR WOUNDS | Ekare Inc. | SABOKTAKIN, MARJAN | 3797 | §103 | Final Rejection | — | Pending | Feb 19, 2026 |
| 19433400 | LYOPHILIZED SOVATELTIDE-BASED INJECTABLE FORMULATION AND A PROCESS FOR PREPARATION | Pharmazz, Inc. | BERHANE, SELAM | 1675 | §102 | Non-Final OA | — | Pending | Dec 26, 2025 |
| 19489804 | WHEEL SUSPENSION FOR A MOTOR VEHICLE | Muhr Und Bender Kg | TO, TOAN C | 3614 | §112 | Non-Final OA | — | Pending | Dec 03, 2025 |
| 19482917 | CONTROLLER FOR A MILKING PLANT, COMPUTER-IMPLEMENTED METHOD, COMPUTER PROGRAM AND NON-VOLATILE DATA CARRIER | Delaval Holding AB | DENNIS, KEVIN M | 3647 | §102§103§112 | Non-Final OA | — | Pending | Nov 10, 2025 |
| 19228139 | RESOURCE-SAVING CLOSURE DEVICE | BERICAP Holding GmbH | SMALLEY, JAMES N | 3733 | §102§103§112 | Non-Final OA | — | Pending | Jun 04, 2025 |
| 19223202 | Milking Robot Controller, Method therefore, Computer Program and Non-Volatile Data Carrier | Delaval Holding AB | NGUYEN, ROBERT T | 3642 | §103§112 | Non-Final OA | — | Pending | May 30, 2025 |
| 19123637 | DEHUMIDIFYING SYSTEM | Munters Europe Aktiebolag | VAZQUEZ, ANA M | 3763 | §103 | Non-Final OA | — | Pending | Apr 23, 2025 |
| 19181886 | DEVICE, SYSTEM AND METHOD FOR INSPECTING THREE-DIMENSIONAL OBJECTS | Isra Vision GmbH | KO, TONY | 2878 | §112 | Non-Final OA | — | Pending | Apr 17, 2025 |
| 19120100 | MEDICAL ENDODEVICE | UNIVERSITÄT BASEL | SAHAND, SANA | 3796 | §101§103§112 | Non-Final OA | — | Pending | Apr 10, 2025 |
| 19114020 | METHOD FOR MANUFACTURING A DENTAL PROSTHESIS PART, ADAPTER, BLANK AND SET OF ADAPTER AND BLANK, SET OF SEVERAL ADAPTERS | Ceramist One GmbH | LUCCHESI, NICHOLAS D | 3772 | §102§103§112 | Non-Final OA | — | Pending | Mar 21, 2025 |
| 18985583 | ENDOSCOPE WITH INERTIAL MEASUREMENT UNITS AND/OR HAPTIC INPUT CONTROLS | Elements Endoscopy Inc. | WOO, JAE KYUN | 3795 | §102§103§112 | Non-Final OA | — | Pending | Dec 18, 2024 |
| 18872988 | EVALUATION OF CONVERGENCE TIME AND ADJUSTMENT BASED ON EVALUATION OF CONVERGENCE TIME | Mercedes-Benz Group AG | BEDEWI, RAMI NABIH | 3666 | §101§102§103 | Final Rejection | 84d | Pending | Dec 09, 2024 |
| 18971848 | ANTI-CLAUDIN-6 CONJUGATES | Adc Therapeutics SA | PETRASH, HILARY ANN | 1644 | §103DP | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18969940 | ANTI-PSMA ANTIBODY CONJUGATES | Adc Therapeutics SA | PETRASH, HILARY ANN | 1644 | §103Other | Non-Final OA | 41d | Pending | Dec 05, 2024 |
| 18957184 | TESTOSTERONE AND ESTRADIOL TRANSDERMAL SPRAY | Celista Pharmaceuticals LLC | SONG, JIANFENG | 1613 | §103§112DP | Non-Final OA | — | Pending | Nov 22, 2024 |
| 18946353 | INFORMATION PROCESSING METHOD, NON-TRANSITORY STORAGE MEDIUM, AND INFORMATION PROCESSING APPARATUS | Tsz Tat Chu | MAHROUKA, WASSIM | 2665 | §101§103§112 | Non-Final OA | — | Pending | Nov 13, 2024 |
| 18938929 | QUALITY CONTROL METHODS FOR AUTOMATED CELL PROCESSING | Lonza Walkersville, Inc. | WESTON, ALYSSA G | 1633 | §103§112DP | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18860366 | COMBINATION OF ALBUTEROL AND BUDESONIDE FOR THE TREATMENT OF ASTHMA | AstraZeneca AB | YOUNG, MICAH PAUL | 1618 | §102§103 | Non-Final OA | — | Pending | Oct 25, 2024 |
| 18923071 | COMPACT MIXED ARRAY IMAGING PROBE | Deepsight Technology, Inc. | FARAG, AMAL ALY | 3798 | §102§103§112 | Non-Final OA | — | Pending | Oct 22, 2024 |
| 18889738 | TREATMENT APPARATUS AND METHOD FOR PROVIDING CONTROL DATA FOR AN OPHTHALMOLOGICAL LASER OF A TREATMENT APPARATUS FOR THE LASER-INDUCED REFRACTIVE INDEX CHANGE | Schwind Eye-Tech-Solutions GmbH | FAIRCHILD, MALLIKA DIPAYAN | 3792 | §101 | Non-Final OA | — | Pending | Sep 19, 2024 |
| 18886028 | MULTI-USE ENDOSCOPES AND ASSOCIATED SYSTEMS AND METHODS | Elements Endoscopy, Inc. | LONDON, STEPHEN FLOYD | 3795 | §102§103§112DP | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18841618 | TOPICAL COMPOSITIONS AND USES THEROF | Topadur Pharma AG | SHTERENGARTS, SAMANTHA L | 1623 | §103§112DP | Non-Final OA | — | Pending | Aug 26, 2024 |
| 18840561 | SAMPLE PREPARATION FOR GLYCOPROTEOMIC ANALYSIS THAT INCLUDES DIAGNOSIS OF DISEASE | VENN BIOSCIENCES CORPORATION | FRANK, RODNEY T | 2855 | §103§112 | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18798864 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | Entera Bio Ltd. | PALENIK, JEFFREY T | 1615 | §103 | Final Rejection | — | Pending | Aug 09, 2024 |
| 18798508 | GUANINE-RICH OLIGONUCLEOTIDES | Kuros US LLC | CROW, ROBERT THOMAS | 1683 | §103§112 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18836057 | PHARMACEUTICAL COMPOSITION OF LIFITEGRAST AND LOTEPREDNOL ETABONATE | Orbicular Pharmaceutical Technologies Private Limited | RICCI, CRAIG D | §102§103§112 | Non-Final OA | — | Pending | Aug 06, 2024 | |
| 18835518 | 3-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | Aurigene Discovery Technologies Limited | BURKETT, DANIEL JOHN | 1624 | §102§112 | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18780030 | METHODS OF CELL SELECTION AND MODIFYING CELL METABOLISM | LONZA LTD | PAK, YONG D | 1652 | §103§112 | Non-Final OA | — | Pending | Jul 22, 2024 |
| 18776688 | METHOD FOR PROVIDING CONTROL DATA FOR AN OPHTHALMOLOGICAL LASER OF A TREATMENT APPARATUS | Schwind Eye-Tech-Solutions GmbH | HOUGH, JESSANDRA F | 3796 | §101§103 | Non-Final OA | 29d | Pending | Jul 18, 2024 |
| 18772698 | METHOD FOR PROVIDING CONTROL DATA FOR AN OPHTHALMOLOGICAL LASER OF A TREATMENT APPARATUS, CONTROL DEVICE THEREFOR, TREATMENT APPARATUS, COMPUTER PROGRAM PRODUCT AND COMPUTER-READABLE MEDIUM | Schwind Eye-Tech-Solutions GmbH | MARSH, OWEN LEWIS | 3796 | §101§102§103§112 | Non-Final OA | 29d | Pending | Jul 15, 2024 |
| 18728675 | FUNCTIONALIZED AMINOTHIAZOLES | Leadxpro AG | REDWOOD, CHRISTOPHER EVAN | 1629 | §103 | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18771844 | SECURE RECONSTITUTION DEVICE | Duoject Medical Systems Inc. | DEAK, LESLIE R | 3799 | DP | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18769485 | Midscale Model For Organic Growth and Phasing | LONZA LTD | KIPOUROS, HOLLY MICHAELA | 1799 | §102§112 | Non-Final OA | — | Pending | Jul 11, 2024 |
| 18766913 | METHOD FOR PROVIDING CONTROL DATA FOR AN OPHTHALMOLOGICAL LASER OF A TREATMENT APPARATUS | Schwind Eye-Tech-Solutions GmbH | HILSMIER, HEIDI ANN | 3796 | §101§102§103 | Non-Final OA | 34d | Pending | Jul 09, 2024 |
| 18762112 | TOPICAL FORMULATIONS AND USES THEREOF | Sun Pharmaceutical Industries, Ltd. | KASSA, TIGABU | §101§103§112Other | Non-Final OA | — | Pending | Jul 02, 2024 | |
| 18724799 | SELF-ADMINISTRATION INJECTION DEVICE FOR RISPERIDONE | Orbicular Pharmaceutical Technologies Private Limited | WHITROCK, ZACHARIAH KIRBY | 3783 | §103§112 | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18754402 | CELL CULTURE AND TISSUE ENGINEERING SYSTEMS WITH CONTROLLED ENVIRONMENTAL ZONES | Octane Biotech Inc. | HENKEL, DANIELLE B | 1799 | §102§103§112 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18721640 | METHOD FOR MANUFACTURING AN ARRANGEMENT FOR CONDENSING A GASEOUS LIQUID INTO LIQUID STATE | Aktiebolaget Scarab Development | GROSS, CARSON | 1746 | §103§112 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18721646 | ARRANGEMENT AND PLATE FOR CONDENSING A GASEOUS LIQUID INTO LIQUID STATE | Aktiebolaget Scarab Development | BUI, ANH HUYNH NGOC | 1773 | §102§103§112 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18720675 | PROSTATE CANCER CLINICAL STATUS MARKERS | UNIVERSITAET ZUERICH | IVICH, FERNANDO NMN | 1678 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 17, 2024 |
| 18680666 | INTRALUMINAL LOCAL DRUG DELIVERY | Isola Therapeutics, Inc. | SCHMIDT, EMILY LOUISE | 3783 | §102§103§112 | Non-Final OA | — | Pending | May 31, 2024 |
| 18678376 | DNA-BASED ADAPTOME PROFILING FOR MINIMAL RESIDUAL DISEASE QUANTIFICATION IN LYMPHOID MALIGNANCIES | Milaboratories Inc. | BROWN, MINDY G | 1683 | §112 | Non-Final OA | 16d overdue | Pending | May 30, 2024 |
| 18675357 | CELLULOSIC COMPOSITE | Woodcomposite Sweden AB | NERANGIS, VICKEY M | 1763 | §103Other | Non-Final OA | 33d | Pending | May 28, 2024 |
| 18675209 | CELLULOSIC COMPOSITE | Woodcomposite Sweden AB | NERANGIS, VICKEY M | 1763 | §103 | Non-Final OA | 75d | Pending | May 28, 2024 |
| 18706231 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | Targimmune Therapeutics AG | FAY, ZOHREH ALEMZADEH | 1617 | §112Other | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18705455 | SPRAY-DRIED COMPOSITIONS AND METHODS OF PREPARATION | National University Of Singapore | PEEBLES, KATHERINE | 1617 | §103§112 | Final Rejection | 34d | Pending | Apr 26, 2024 |
| 18705292 | MICROFLUIDIC CELL CULTURING DEVICE | UNIVERSITÄT BERN | BRIDGES, DONAVAN LEE | 1758 | §102§103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18645797 | METHOD FOR PROVIDING CONTROL DATA FOR A LASER OF A PROCESSING APPARATUS, CONTROL DEVICE, COMPUTER PROGRAM AND COMPUTER-READABLE MEDIUM | Schwind Eye-Tech-Solutions GmbH | SANDERS, JOSHUA T | 2119 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18700883 | SLEEP-BASED DETECTION AND INTERVENTION SYSTEM | UNIVERSITÄT BERN | DIETZ, NOE ROBERT | 3791 | §102§103§112 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18633844 | PD-1/TIGIT BINDING PROTEINS FOR CANCER TREATMENT | MedImmune, LLC | ALLEN, MARIANNE P | 1647 | §103§112Other | Non-Final OA | — | Pending | Apr 12, 2024 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial77.9% of resolved applications prosecuted by Medler Ferro Woodhouse & Mills Pllc were allowed, across 2,599 applications in USPTO records.
3.55 office actions per allowed application on average.
167 pending office actions as of October 2026, for 89 clients, before 155 examiners in 88 art units.
